{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:04:03Z","timestamp":1787598243529,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.msard.2021.102843","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T13:43:44Z","timestamp":1613396624000},"page":"102843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis"],"prefix":"10.1016","volume":"50","author":[{"given":"Yupeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxiao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.msard.2021.102843_bib0001","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","article-title":"Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study","volume":"263","author":"Annovazzi","year":"2016","journal-title":"Journal of Neurology"},{"issue":"10","key":"10.1016\/j.msard.2021.102843_bib0002","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Multiple Sclerosis Journal"},{"issue":"4","key":"10.1016\/j.msard.2021.102843_bib0003","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00415-018-8771-5","article-title":"Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study","volume":"265","author":"Cabre","year":"2018","journal-title":"Journal of Neurology"},{"issue":"8","key":"10.1016\/j.msard.2021.102843_bib0004","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/imj.12207","article-title":"Experience with low-dose rituximab in off-label indications at two tertiary hospitals","volume":"43","author":"Chay","year":"2013","journal-title":"Intern Med J"},{"key":"10.1016\/j.msard.2021.102843_bib0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","article-title":"Monitoring CD27\u00a0+\u00a0memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study","volume":"373","author":"Cohen","year":"2017","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1016\/j.msard.2021.102843_bib0006","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-018-1039-7","article-title":"Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options","volume":"79","author":"Collongues","year":"2019","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.msard.2021.102843_bib0007","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458515602337","article-title":"Efficacy of rituximab in refractory neuromyelitis optica","volume":"22","author":"Collongues","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"issue":"10206","key":"10.1016\/j.msard.2021.102843_bib0008","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"The Lancet"},{"issue":"7","key":"10.1016\/j.msard.2021.102843_bib0009","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2021.102843_bib0010","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.msard.2021.102843_bib0011","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jneuroim.2019.04.007","article-title":"Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review","volume":"332","author":"Enriquez","year":"2019","journal-title":"J Neuroimmunol"},{"issue":"8","key":"10.1016\/j.msard.2021.102843_bib0012","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.nrl.2014.09.001","article-title":"Evaluaci\u00f3n del uso de rituximab en la neuromielitis \u00f3ptica","volume":"30","author":"Fern\u00e1ndez-Meg\u00eda","year":"2015","journal-title":"Neurolog\u00eda"},{"issue":"1","key":"10.1016\/j.msard.2021.102843_bib0013","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jns.2013.02.024","article-title":"Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases","volume":"328","author":"Gredler","year":"2013","journal-title":"Journal of the Neurological Sciences"},{"issue":"7","key":"10.1016\/j.msard.2021.102843_bib0014","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Multiple Sclerosis Journal"},{"issue":"4","key":"10.1016\/j.msard.2021.102843_bib0015","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1474-4422(20)30062-4","article-title":"Old and new breakthroughs in neuromyelitis optica","volume":"19","author":"Hartung","year":"2020","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.msard.2021.102843_bib0016","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"1-2","key":"10.1016\/j.msard.2021.102843_bib0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2012.09.024","article-title":"Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders","volume":"324","author":"Ip","year":"2013","journal-title":"Journal of the Neurological Sciences"},{"issue":"11","key":"10.1016\/j.msard.2021.102843_bib0018","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.msard.2021.102843_bib0019","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.msard.2021.102843_bib0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"issue":"11","key":"10.1016\/j.msard.2021.102843_bib0021","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.msard.2021.102843_bib0022","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/jnnp-2018-318465","article-title":"Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment","volume":"90","author":"Kim","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.msard.2021.102843_bib0023","doi-asserted-by":"crossref","first-page":"e82325","DOI":"10.1371\/journal.pone.0082325","article-title":"Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.msard.2021.102843_bib0024","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurology"},{"issue":"15","key":"10.1016\/j.msard.2021.102843_bib0025","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1212\/WNL.0b013e31824f8069","article-title":"Clinical spectrum of CNS aquaporin-4 autoimmunity","volume":"78","author":"Kim","year":"2012","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.msard.2021.102843_bib0026","doi-asserted-by":"crossref","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","article-title":"Racial differences in neuromyelitis optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2021.102843_bib0027","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2021.102843_bib0028","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2017.12.021","article-title":"Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab","volume":"316","author":"Li","year":"2018","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/j.msard.2021.102843_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.004","article-title":"Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder","volume":"317","author":"Lin","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"1-2","key":"10.1016\/j.msard.2021.102843_bib0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.msard.2021.102843_bib0031","first-page":"e46","article-title":"Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children","volume":"1","author":"Longoni","year":"2014","journal-title":"Neurology : neuroimmunology & neuroinflammation"},{"key":"10.1016\/j.msard.2021.102843_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101933","article-title":"A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders","volume":"40","author":"Lu","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1016\/j.msard.2021.102843_bib0033","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamaneurol.2013.3583","article-title":"Individualized rituximab treatment for neuromyelitis Optica spectrum disorders","volume":"70","author":"McKeon","year":"2013","journal-title":"JAMA Neurol"},{"issue":"13","key":"10.1016\/j.msard.2021.102843_bib0034","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1177\/1352458517730131","article-title":"Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders","volume":"24","author":"Mealy","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"3","key":"10.1016\/j.msard.2021.102843_bib0035","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurology"},{"issue":"9","key":"10.1016\/j.msard.2021.102843_bib0036","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"Journal of neurology"},{"issue":"15","key":"10.1016\/j.msard.2021.102843_bib0037","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2021.102843_bib0038","first-page":"e61","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurology : neuroimmunology & neuroinflammation"},{"issue":"15","key":"10.1016\/j.msard.2021.102843_bib0039","doi-asserted-by":"crossref","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","article-title":"Evaluation of efficacy and tolerability of first-line therapies in NMOSD","volume":"94","author":"Poupart","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2021.102843_bib0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.msard.2021.102843_bib0041","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2021.102843_bib0042","first-page":"155","article-title":"Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: A prospective observation in Iranian cases","volume":"11","author":"Seyed","year":"2020","journal-title":"Caspian J Intern Med"},{"issue":"3","key":"10.1016\/j.msard.2021.102843_bib0043","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00415-019-09180-9","article-title":"Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study","volume":"266","author":"Shaygannejad","year":"2019","journal-title":"Journal of Neurology"},{"issue":"8","key":"10.1016\/j.msard.2021.102843_bib0044","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1016\/j.msard.2021.102843_bib0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.msard.2016.02.014","article-title":"Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment","volume":"7","author":"Tackley","year":"2016","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"4","key":"10.1016\/j.msard.2021.102843_bib0046","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"The Lancet Neurology"},{"issue":"5","key":"10.1016\/j.msard.2021.102843_bib0047","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.msard.2021.102843_bib0048","first-page":"e317","article-title":"Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study","volume":"4","author":"Valentino","year":"2017","journal-title":"Neurology : neuroimmunology & neuroinflammation"},{"issue":"10","key":"10.1016\/j.msard.2021.102843_bib0049","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1177\/0883073814553974","article-title":"Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment","volume":"30","author":"Weinfurtner","year":"2015","journal-title":"Journal of Child Neurology"},{"issue":"12","key":"10.1016\/j.msard.2021.102843_bib0050","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nrneurol.2011.154","article-title":"White matter disease: optimizing rituximab therapy for neuromyelitis optica","volume":"7","author":"Wingerchuk","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.msard.2021.102843_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102166","article-title":"Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials","volume":"43","author":"Xue","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"8","key":"10.1016\/j.msard.2021.102843_bib0052","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2021.102843_bib0053","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Z\u00e9phir","year":"2015","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1016\/j.msard.2021.102843_bib0054","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","article-title":"Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study","volume":"117","author":"Zhang","year":"2017","journal-title":"Acta Neurol Belg"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:55:07Z","timestamp":1761900907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821001097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":54,"alternative-id":["S2211034821001097"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102843","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102843"}}